Cited by 729Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Open access

Lenz, Heinz-Josef, Van Cutsem, Eric, Luisa Limon, Maria, Wong, Ka Yeung Mark, Hendlisz, Alain, Aglietta, Massimo, García-Alfonso, Pilar, Neyns, Bart, Luppi, Gabriele, Cardin, Dana B., Dragovich, Tomislav, Shah, Usman, Abdullaev, Sandzhar, Gricar, Joseph, Ledeine, Jean-Marie, Overman, Michael James, Lonardi, Sara·2022·Journal of Clinical Oncology

DOI 10.1200/jco.21.01015

Open this paper in CoChat — free account Open PDF

Abstract

PURPOSE: Nivolumab received US Food and Drug Administration approval as a single agent or in combination with ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) that progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan based on CheckMate 142. Presented are results of nivolumab plus low-dose ipilimumab in the first-line therapy cohort from the phase II CheckMate 142 study. PATIENTS AND METHODS: Patients with no prior treatment in the metastatic setting for MSI-H/dMMR CRC were treated with nivolumab every 2 weeks plus low-dose ipilimumab every 6 weeks until disease progression. The primary end point was objective response rate (investigator assessment; RECIST v1.1). RESULTS: Median age of treated patients was 66 years (N = 45). Median follow-up was 29.0 months. Objective response rate and disease control rate were 69% (95% CI, 53 to 82) and 84% (95% CI, 70.5 to 93.5), respectively, with 13% complete response rate. Median duration of response was not reached; 74% of responders had ongoing responses at data cutoff. Median progression-free survival and median overall survival were not reached with minimum follow-up of 24.2 months (24-month rates, 74% and 79%, respectively). Clinical benefit was observed regardless of baseline demographic and tumor characteristics, including BRAF or KRAS mutation status. In a post hoc analysis, of 14 patients who discontinued treatment and did not receive subsequent therapy, 10 remained progression-free. Patient-reported outcomes were stable over the treatment period. Grade 3-4 treatment-related adverse events occurred in 22% of patients; 13% discontinued because of any-grade treatment-related adverse events. CONCLUSION: Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for MSI-H/dMMR mCRC. Based on these promising data, randomized studies are warranted.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.21.01015

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Colorectal cancer statistics, 2017
Siegel, R. L., Miller, K. D., Fedewa, S. A., Ahnen, D. J., Meester, R. G. S., Barzi, A., & Jemal, A. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21395 · Cited by 3,807
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713

Flagged first, then by citations

Show all 30 references

Research works printed but not linked: 3

2020, Opdivo (nivolumab) Injection for Intravenous Use [prescribing information]
National Comprehensive Cancer Network, Colon Cancer (Version 2.2021)
National Comprehensive Cancer Network, Rectal Cancer (Version 1.2021)

Sorted by citations

Items 201–300 of 729

Updated outcomes and exploratory analysis of RENMIN-215: tislelizumab plus fruquintinib and fecal microbiota transplantation in refractory microsatellite stable metastatic colorectal cancer
Zhao, W. (2024) · American Journal of Cancer Research · doi:10.62347/xkuj3012 · Cited by 16
LRG1-Targeted Camptothecin Nanomicelles with Simultaneous Delivery of Olaparib for Enhanced Colorectal Cancer Chemotherapy
Du, L., Min, H., Meng, Y., Zhang, K., Wang, L., Zhang, Y., Sun, P., Zhang, W., Qi, Y., & Wu, G. (2025) · Nano Letters · doi:10.1021/acs.nanolett.4c05354 · Cited by 18
Colorectal cancer: highlight the clinical research current progress
Wang, M., Zheng, C., Wang, Z., Li, R., Zhang, W., Zhong, Y., Wu, H., Zhang, Q., Han, D., Zhu, Y., et al. (2025) · Holistic Integrative Oncology · doi:10.1007/s44178-025-00152-w · Cited by 18
Immune checkpoint blockade therapy for BRAF mutant metastatic colorectal cancer: the efficacy, new strategies, and potential biomarkers
Zhong, J., Sun, Z., Li, S., Liu, Y., Cao, Y., & Bao, J. (2023) · Discover Oncology · doi:10.1007/s12672-023-00718-y · Cited by 16
Advancements in the Management of Synchronous Colorectal Liver Metastases: A Comprehensive Review of Surgical, Systemic, and Local Treatment Modalities
Karaoğlan, B. B., Öz, D. K., Araz, M., Akyol, C., & Utkan, G. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01548-z · Cited by 16
Ginsenosides: an immunomodulator for the treatment of colorectal cancer
Qian, J., Jiang, Y., & Hu, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1408993 · Cited by 16
Microsatellite instability and chemosensitivity in solid tumours
Cherri, S., Oneda, E., Noventa, S., Melocchi, L., & Zaniboni, A. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221099347 · Cited by 18
Assessment and treatment considerations for patients with colorectal liver metastases: AHPBA consensus guideline and update for surgeons
Yohanathan, L., Chopra, A., Simo, K. A., Clancy, T. E., Khithani, A. S., Anaya, D. A., Maegawa, F. B., Sheikh, M. R., Raoof, M., Jacobs, M. R., et al. (2024) · HPB · doi:10.1016/j.hpb.2024.12.006 · Cited by 16
Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells
Singer, M., Valerin, J. B., Zhang, Z., Zhang, Z., Dayyani, F., Yaghmai, V., Choi, A., Imagawa, D. K., & Abi‐Jaoudeh, N. (2025) · Cells · doi:10.3390/cells14030166 · Cited by 17
Strategies to Optimize Treatment for Locally Advanced Rectal Cancer
Hu, X., Xue, Z., He, K., Tian, Y., Chen, Y., Zhao, M., Yu, J., & Yue, J. (2022) · Cancers · doi:10.3390/cancers15010219 · Cited by 15
Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier
Frederico, S. C., Darling, C., Bielanin, J. P., Dubinsky, A. C., Zhang, X., Hadjipanayis, C. G., & Kohanbash, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1057567 · Cited by 15
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer
Lavacchi, D., Roviello, G., Guidolin, A., Romano, S., Venturini, J., Caliman, E., Vannini, A., Giommoni, E., Pellegrini, E., Brugia, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065840 · Cited by 17
Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements
Cann, C., LaPelusa, M. B., Cimino, S. K., & Eng, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1176950 · Cited by 16
Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer
Kano, Y., Suenaga, M., & Uetake, H. (2023) · Current Oncology · doi:10.3390/curroncol30070480 · Cited by 18
Anti-Tumor Efficacy of Oleuropein-Loaded ZnO/Au Mesoporous Silica Nanoparticle in 5-FU-Resistant Colorectal Cancer Cells
Park, S. M., Kim, D. Y., Lee, K. H., Shin, Y., Han, S.-C., & Kwon, S. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s439392 · Cited by 15
The future of cancer vaccines against colorectal cancer
Jia, W., Shen, X., Guo, Z., Cheng, X., & Zhao, R. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2341744 · Cited by 16
Improving the efficacy of immunotherapy for colorectal cancer: Targeting tumor microenvironment-associated immunosuppressive cells
Zou, D., Xin, X., Xu, Y., Xu, H., Huang, L., & Xu, T. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36446 · Cited by 16
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)
Barroso‐Sousa, R., Zañudo, J. G. T., Li, T., Reddy, S. M., Emens, L. A., Kuntz, T. M., Silva, C. A. C., AlDubayan, S. H., Chu, H., Overmoyer, B. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59695-1 · Cited by 15
Emerging drug targets for colon cancer: A preclinical assessment
Crutcher, M. M., Baybutt, T. R., Kopenhaver, J. S., Snook, A. E., & Waldman, S. A. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2039119 · Cited by 15
Microsatellite instability assessment is instrumental for Predictive, Preventive and Personalised Medicine: status quo and outlook
Styk, J., Pös, Z., Pös, O., Radvánszky, J., Turnova, E. H., Buglyó, G., Klimová, D., Budiš, J., Repiská, V., Nagy, B., et al. (2023) · The EPMA Journal · doi:10.1007/s13167-023-00312-w · Cited by 18
Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic colorectal cancer: A phase I nonrandomized clinical trial
Xiao, A., Li, X., Wang, C., Ye, J., & Fakih, M. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115111 · Cited by 17
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors
Gallois, C., Ambrosini, M., Lonardi, S., Alouani, E. L., Guimbaud, R., Overman, M. J., Sinicrope, F. A., Mazard, T., Decraecker, M., Ros, J., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115645 · Cited by 15
Self-citation
Next‐Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy
Bautista, J., Echeverría, C. E., Maldonado-Noboa, I., Adatty-Molina, J., Urresta, S. S., Coral-Riofrio, E. C., Araujo‐Abad, S., Kyriakidis, N. C., & López-Cortés, A. (2026) · Journal of Immunology Research · doi:10.1155/jimr/7864229 · Cited by 16
Biomarkers in the development of individualized treatment regimens for colorectal cancer
Crutcher, M. M., & Waldman, S. A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1062423 · Cited by 14
Outcome of Patients With Early-Stage Mismatch Repair Deficient Colorectal Cancer Receiving Neoadjuvant Immunotherapy: A Systematic Review
Chakrabarti, S., Grewal, U. S., Vora, K. B., Parikh, A. R., Almader‐Douglas, D., Mahipal, A., & Sonbol, M. B. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00182 · Cited by 15
Turning up the heat: CTLA4 blockade in urothelial cancer
Stockem, C. F., Galsky, M. D., & van der Heijden, M. S. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00801-7 · Cited by 15
Improving the efficiency of immune checkpoint inhibitors for metastatic pMMR/MSS colorectal cancer: Options and strategies
Yang, C., Zhao, L., Lin, Y., Wang, S., Ye, Y., & Shen, Z. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104204 · Cited by 16
Preoperative chemotherapy in upfront resectable colorectal liver metastases: New elements for an old dilemma?
Bernardi, L., Roesel, R., Aghayan, D. L., Majno-Hurst, P. E., Dosso, S. D., & Cristaudi, A. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102696 · Cited by 14
Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D
Kim, R. D., Tehfe, M. A., Kavan, P., Chaves, J., Kortmansky, J. S., Chen, E. X., Lieu, C. H., Wong, L., Fakih, M., Spencer, K. R., et al. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.03.001 · Cited by 16
Colorectal Cancer: Genetic Underpinning and Molecular Therapeutics for Precision Medicine
Dosunmu, G. T., & Shergill, A. P. (2024) · Genes · doi:10.3390/genes15050538 · Cited by 16
Biomarker Testing Disparities in Metastatic Colorectal Cancer
Sabbagh, S., Herrán, M., Hijazi, A., Jabbal, I. S., Mohanna, M., Dominguez, B. G., Itani, M., Sarna, K., Liang, H., Nahleh, Z. A., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.19142 · Cited by 14
Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
Yu, I. S., Aubin, F., Goodwin, R. A., Loree, J. M., Mather, C. A., Sheffield, B. S., Snow, S. L., & Gill, S. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221111705 · Cited by 17
The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients
Germani, M. M., Carullo, M., Boccaccino, A., Conca, V., & Masi, G. (2022) · Cancers · doi:10.3390/cancers14184453 · Cited by 14
Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches
Pum, K., LaRocca, C. J., Goffredo, P., Subramanian, S., Lou, E., & Prakash, A. (2025) · JCO oncology advances. · doi:10.1200/oa-24-00077 · Cited by 15
Immune escape in colorectal cancer: Mechanisms and challenges of immune checkpoint inhibitor resistance
Yousefi, M., Gharaie, D., Javan, M. R., & Khosrojerdi, A. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115986 · Cited by 15
Concordance in detection of microsatellite instability by PCR and NGS in routinely processed tumor specimens of several cancer types
Bartels, S., Grote, I., Wagner, M., Boog, J., Schipper, E., Reineke‐Plaaß, T., Kreipe, H. H., & Lehmann, U. (2023) · Cancer Medicine · doi:10.1002/cam4.6293 · Cited by 13
Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response
Nemunaitis, J. J., Stanbery, L., Willoughby, D., Bognar, E., Brun, S., Walter, A., Monk, B. J., Rocconi, R. P., Choucair, K., & Coleman, R. L. (2023) · Cancers · doi:10.3390/cancers15235616 · Cited by 14
Mutational signatures of colorectal cancers according to distinct computational workflows
Battuello, P., Corti, G., Bartolini, A., Lorenzato, A., Sogari, A., Russo, M., Nicolantonio, F. D., Bardelli, A., & Crisafulli, G. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae249 · Cited by 13
Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?
Werner, W., Kuzminskaya, M., Lurje, I., Tacke, F., & Hammerich, L. (2024) · Seminars in Liver Disease · doi:10.1055/a-2334-8311 · Cited by 14
Spatially Resolved, Multiregion Proteomics for Prediction of Immunotherapy Outcome in Deficient Mismatch Repair Metastatic Colorectal Cancer
Saberzadeh-Ardestani, B., Liu, Z., Stein, M. I., Sherman, W. A., Trussoni, C. E., Abbott, C. W., Yan, D., Smith, S., Shanmugam, K., Graham, R. P., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0853 · Cited by 13
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors
Ziranu, P., Pretta, A., Pozzari, M., Maccioni, A., Badiali, M., Fanni, D., Lai, E., Donisi, C., Persano, M., Gerosa, C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-31538-3 · Cited by 15
Identification of VVD-214/RO7589831, a Clinical-Stage, Covalent Allosteric Inhibitor of WRN Helicase for the Treatment of MSI-High Cancers
Kikuchi, S., Green, J. C., Rogness, D. C., Lam, B., Owyang, Z. A., Malmstrom, R. D., Tabatabaei, A., Snead, A. N., Hoffman, M. A., Bernard, S. M., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01805 · Cited by 15
POLE-Mutant Colon Cancer Treated with PD-1 Blockade Showing Clearance of Circulating Tumor DNA and Prolonged Disease-Free Interval
Bikhchandani, M., Amersi, F. F., Hendifar, A. E., Gangi, A., Osipov, A., Zaghiyan, K. N., Atkins, K. M., Cho, M. T., Aguirre, F. P., Hazelett, D. J., et al. (2023) · Genes · doi:10.3390/genes14051054 · Cited by 14
Immunotherapy in mismatch repair-deficient metastatic colorectal cancer – Outcome and novel predictive markers
Stemmer, A., Margalit, O., Serpas, V., Strauss, G. Z., Thomas, J. V., Shah, P., Tau, N., Levanon, K., Shacham‐Shmueli, E., Kopetz, S., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113495 · Cited by 12
Self-citation
Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE
Cartwright, E., Slater, S., Saffery, C., Tran, A., Turkes, F., Smith, G. A., Aresu, M., Kohoutová, D., Terlizzo, M., Zhitkov, O., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102971 · Cited by 12
Nivolumab and Ipilimumab Acting as Tormentors of Advanced Tumors by Unleashing Immune Cells and Associated Collateral Damage
Khan, B., Qahwaji, R. M., Alfaifi, M. S., & Mobashir, M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060732 · Cited by 15
Third-line treatment and beyond in metastatic colorectal cancer: What do we have and what can we expect?
Miguel, C. A.-D., Jiménez-Castro, J., Sanchez-Vegas, A., Díaz-López, S., & Chaves-Conde, M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104454 · Cited by 13
A comprehensive overview of the molecular features and therapeutic targets in BRAF V600E ‐mutant colorectal cancer
Gu, R., Fang, H., Wang, R., Dai, W., & Cai, G. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1764 · Cited by 14
Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review
Kciuk, M., Wanke, K., Kruczkowska, W., Marciniak, B., & Kontek, R. (2025) · Molecules · doi:10.3390/molecules30132686 · Cited by 14
Fusobacterium nucleatum load in MSI colorectal cancer subtypes
Ono, T., Yamaguchi, T., Takao, M., Kojika, E., Iijima, T., & Horiguchi, S. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02218-5 · Cited by 13
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)
Ciardiello, D., Chiarazzo, C., Famiglietti, V., Damato, A., Pinto, C., Zampino, M. G., Castellano, G., Gervaso, L., Zaniboni, A., Oneda, E., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100567 · Cited by 13
Immunotherapy combined with radiotherapy to reverse immunosuppression in microsatellite stable colorectal cancer
Wu, C., Shao, Y., & Gu, W. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03091-y · Cited by 13
Crosstalk between ILC3s and Microbiota: Implications for Colon Cancer Development and Treatment with Immune Check Point Inhibitors
Drommi, F., Calabrò, A., Vento, G., Pezzino, G., Cavaliere, R., Omero, F., Muscolino, P., Granata, B., D’Anna, F., Silvestris, N., et al. (2023) · Cancers · doi:10.3390/cancers15112893 · Cited by 14
Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing Research
Kumar, R. N., Kim, J., Deek, M. P., Eskander, M. F., Gulhati, P., In, H., Kennedy, T. J., Shah, M. M., Grandhi, M. S., Berim, L. D., et al. (2023) · Current Oncology · doi:10.3390/curroncol30070473 · Cited by 11
Increased Response to Immune Checkpoint Inhibitors with Dietary Methionine RestrictionPreprint
Morehead, L. C., Garg, S., Wallis, K., Siegel, E. R., Tackett, A. J., & Miousse, I. R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.05.535695 · Cited by 12
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer
Gonzalez, N. S., López-Valbuena, D., Gómez, D., Ros, J., Baraibar, I., Salvà, F., Tabernero, J. M., & Élez, E. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2160316 · Cited by 11
A Review of Translational Research for Targeted Therapy for Metastatic Colorectal Cancer
Ruff, S. M., & Pawlik, T. M. (2023) · Cancers · doi:10.3390/cancers15051395 · Cited by 12
Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (V. 2023)
Ren, L., Zhu, D., Gu, J. F., Jia, B., Li, J., Qin, X., Wang, X., Xu, R., Ye, Y., Zhang, S., et al. (2023) · Clinical Surgical Oncology · doi:10.1016/j.cson.2023.100013 · Cited by 11
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting
Crimini, E., Bielo, L. B., Giachetti, P. P. M. B., Pellizzari, G., Antonarelli, G., Salimbeni, B. T., Repetto, M., Belli, C., & Curigliano, G. (2024) · Cancers · doi:10.3390/cancers16020281 · Cited by 11
Liver transplantation for colorectal cancer with liver metastases
Ueberroth, B. E., Kriss, M. S., Burton, J. R., & Messersmith, W. A. (2025) · The Oncologist · doi:10.1093/oncolo/oyae367 · Cited by 12
Colorectal cancer in adolescent and young adults: epidemiology in Japan and narrative review
Ueno, A., Yokota, M., Ueno, M., & Kawamoto, K. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-98 · Cited by 11
Optimizing the first-line treatment for metastatic colorectal cancer
Cherri, S., Oneda, E., Zanotti, L., & Zaniboni, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1246716 · Cited by 16
Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis
Knisely, A. T., Hinchcliff, E., Fellman, B. M., Mosley, A., Lito, K., Hull, S., Westin, S. N., Sood, A. K., Schmeler, K. M., Taylor, J. S., et al. (2024) · Med · doi:10.1016/j.medj.2024.02.003 · Cited by 11
Investigating the therapeutic promise of drug-repurposed-loaded nanocarriers: A pioneering strategy in advancing colorectal cancer treatment
Mneimneh, A. T., Darwiche, N., & Mehanna, M. M. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124473 · Cited by 11
Immune Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review
Gilson, A., Tan, V., Koessler, T., Meyer, J., Meurette, G., Liot, É., Ris, F., & Delaune, V. (2025) · Cancers · doi:10.3390/cancers17132125 · Cited by 10
Defining the Immune Checkpoint Landscape in Human Colorectal Cancer Highlights the Relevance of the TIGIT/CD155 Axis for Optimizing Immunotherapy
Ducoin, K., Mutala, L. B., Deleine, C., Oger, R., Duchalais, É., Jouand, N., Bossard, C., Jarry, A., & Gervois, N. (2022) · Cancers · doi:10.3390/cancers14174261 · Cited by 10
Nonoperative Management of dMMR/MSI-H Colorectal Cancer following Neoadjuvant Immunotherapy: A Narrative Review
Xiao, B.-Y., Yu, J.-H., & Ding, P.-R. (2023) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0043-1767703 · Cited by 11
Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients
Barbé, R., Belkouchi, Y., Menu, Y., Cohen, R., David, C., Kind, M., Harguem, S., Dawi, L., Hadchiti, J., Selhane, F., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114020 · Cited by 10
Resistance to immune checkpoint inhibitors in colorectal cancer with deficient mismatch repair/microsatellite instability: misdiagnosis, pseudoprogression and/or tumor heterogeneity?
Normanno, N., Caridi, V., Fassan, M., Avallone, A., Ciardiello, F., & Pinto, C. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00231 · Cited by 10
Challenges and Opportunities for Precision Surgery for Colorectal Liver Metastases
O'Connell, R. M., & Hoti, E. (2024) · Cancers · doi:10.3390/cancers16132379 · Cited by 10
Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI
Alig, A. H. S., Modest, D. P., Stintzing, S., Heinrich, K., Geißler, M., von Weikersthal, L. F., Decker, T., Vehling‐Kaiser, U., Held, S., Moosmann, N., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103677 · Cited by 11
Origin, development and therapy of colorectal cancer from the perspective of a biologist and an oncologist
Švec, J., Onhajzer, J., & Kořínek, V. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104544 · Cited by 10
Role of CD47 gene expression in colorectal cancer: a comprehensive molecular profiling study
Arai, H., Gandhi, N. S., Battaglin, F., Wang, J., Algaze, S. D., Jayachandran, P., Soni, S., Zhang, W., Yang, Y., Millstein, J., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010326 · Cited by 10
Self-citation
Pretreatment neutrophil–lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumab
Kasahara, Y., Saijo, K., Ueta, R., Numakura, R., Sasaki, K., Yoshida, Y., Taniguchi, S. H., Ouchi, K., Komine, K., Imai, H., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-79130-7 · Cited by 10
Precision Medicine for Metastatic Colorectal Cancer: Where Do We Stand?
Underwood, P. W., & Pawlik, T. M. (2024) · Cancers · doi:10.3390/cancers16223870 · Cited by 13
In-silico analysis of potential phytochemicals targeting mitogen activating protein kinase-14 (MAPK14) gene in colorectal cancer
Khalid, M., Mateen, R. M., Javed, M., Ali, M., Saqab, M. A. N., Parveen, R., Asimov, A., Bibi, S., Bahadur, A., Iqbal, S., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-05807-2 · Cited by 10
Management of Elderly Colorectal Cancer Patients: A Comprehensive Review Encompassing Geriatric Assessment
Boccaccino, A., Cassaniti, M., Rossini, D., Faccani, L., Casadio, C., & Tamberi, S. (2025) · Cancers · doi:10.3390/cancers17203336 · Cited by 10
Characterization of m6A Methylation Modification Patterns in Colorectal Cancer Determines Prognosis and Tumor Microenvironment Infiltration
Yue, Q., Zhang, Y., Wang, F., Cao, F., Bai, J. Y., & Duan, X. (2022) · Journal of Immunology Research · doi:10.1155/2022/8766735 · Cited by 10
Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer
Liu, C., Xiao, H., Cui, L., Fang, L., Han, S., Ruan, Y., Zhao, W., & Zhang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1039631 · Cited by 10
Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer
Martin, C. M., & Enrico, D. H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.962947 · Cited by 10
Identifying and clinically validating biomarkers for immunotherapy in colorectal cancer
Yeh, Y., Tsai, H., Chen, P.-J., Chen, Y., Su, W., Chang, T., Huang, C., & Wang, J. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2188195 · Cited by 10
Total neoadjuvant treatment and organ preservation strategies in the management of localized rectal cancer: A narrative review and evidence-based algorithm
Borelli, B., Germani, M. M., Carullo, M., Mattioni, R., Manfredi, B., Sainato, A., Rossi, P., Vagli, P., Balestri, R., Buccianti, P., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103985 · Cited by 10
Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic Colorectal Cancer
Gherman, A., Bolunduț, D., Ecea, R., Bălăcescu, L., Curcean, S., Dina, C., Bălăcescu, O., & Cainap, C. I. (2024) · Medicina · doi:10.3390/medicina60030397 · Cited by 10
Cynaroside Induces G1 Cell Cycle Arrest by Downregulating Cell Division Cycle 25A in Colorectal Cancer
Lei, S., Cao, W., Zeng, Z., Wang, L., Lan, J., & Chen, T. (2024) · Molecules · doi:10.3390/molecules29071508 · Cited by 10
Dostarlimab: A promising new PD-1 inhibitor for cancer immunotherapy
Farzeen, Z., Khan, R. R. M., Choudhry, A. R., Pervaiz, M. A., Saeed, Z., Rasheed, S., Shehzad, B., Adnan, A., & Summer, M. (2024) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552241265058 · Cited by 10
Nationwide Real-World Data of Microsatellite Instability and/or Mismatch Repair Deficiency in Cancer: Prevalence and Testing Patterns
Fountzilas, E., Papadopoulos, T., Papadopoulou, E., Gouédard, C., Kourea, E. P., Constantoulakis, P., Μagkou, C., Sfakianaki, M., Kotoula, V., Bantouna, D., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14111076 · Cited by 9
Illudin S inhibits p53-Mdm2 interaction for anticancer efficacy in colorectal cancer
Lee, Y. S., Lee, Y. Y., Park, J., Maksakova, A., Seo, D., Kim, J., Yeom, J. E., Kim, Y., Kim, C., Ryoo, R., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117795 · Cited by 11
Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer
Deming, D. A. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.7067 · Cited by 12
Comparison of survival outcomes for patients with Lynch vs non‐Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapy
Eslinger, C. R., Walden, D. M., McGary, A. K., Emiloju, O. E., Ahn, D. H., Sonbol, M. B., Bekaii‐Saab, T., Zhu, M., Hubbard, J. M., & Wu, C. S.-Y. (2025) · Cancer · doi:10.1002/cncr.35756 · Cited by 9
Tumor Immune Microenvironment and Current Status of Immune Checkpoint Inhibitor Therapy in Colorectal Cancer Liver Metastasis
Cao, D., & Zhou, A. (2025) · Current Oncology · doi:10.3390/curroncol32090493 · Cited by 9
Mismatch Repair Deficiency and the Role of Non-Canonical Functions in Cancer: Diagnosis and Therapeutic Implications
Dąbrowska, A., Mastalerz, J. A., Łapińska, Z., Deszcz, I., Chwiłkowska, A., & Rembiałkowska, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199312 · Cited by 9
Colorectal cancer pathogenesis, oncogenic signaling networks and targeted therapeutic advances
Chen, Y., Zhang, J., Ding, Y., Zhu, F., & Chen, Y. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00433-4 · Cited by 13
Comprehensive Overview of Therapeutic Strategies in Colon Cancer: Chemotherapy, Targeted Therapy, and Immunotherapy
Sulaiman, S. H., Barzani, H. A. H., Omer, R. A., Jawhar, Z. H., & Mohammedsaeed, A. A. (2026) · Cell Biochemistry and Function · doi:10.1002/cbf.70196 · Cited by 9
Role of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer
Shi, L., Xu, Y., & Feng, M. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07689-0 · Cited by 9
Vascular endothelial growth factor inhibitors promote antitumor responses via tumor microenvironment immunosuppression in advanced colorectal cancer
Hamada, Y., Tanoue, K., Kita, Y., Tanabe, K., Hokonohara, K., Wada, M., Hozaka, Y., Oi, H., Nakayama, C., Higashi, M., et al. (2023) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2023.2194011 · Cited by 9
Beyond EGFR inhibitors in advanced colorectal cancer: Targeting BRAF and HER2
Dao, V. A., & Heestand, G. M. (2023) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2023.100960 · Cited by 9
DNA mismatch repair deficient cancer – Emerging biomarkers of resistance to immune checkpoint inhibition
Brooksbank, K., & Martin, S. A. (2023) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2023.106477 · Cited by 10
Exploiting tertiary lymphoid structures gene signature to evaluate tumor microenvironment infiltration and immunotherapy response in colorectal cancer
Xu, Z., Wang, Q., Zhang, Y., Li, X., Wang, M., Zhang, Y., Pei, Y., Li, K., Yang, M., Luo, L., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1383096 · Cited by 8
Mevalonate kinase inhibits anti-tumor immunity by impairing the tumor cell-intrinsic interferon response in microsatellite instability colorectal cancer
Liao, Y., Yang, R., Wang, B., Ruan, Y., Cui, L., Yang, J., Yu, X., Han, S., Yao, Y., Luan, X., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03255-2 · Cited by 8
Predictive biomarkers for immune checkpoint inhibition for patients with colorectal cancer: a comprehensive review
Şahin, İ. H., Saridogan, T., & Kim, R. D. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2530853 · Cited by 8

Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.
Lenz, H., Lonardi, S., Zagonel, V., Cutsem, E. V., Limón, M. L., Wong, K. Y. M., Hendlisz, A., Aglietta, M., Alfonso, P. G., Neyns, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.11 · Cited by 59
Self-citation
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
André, T., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.008 · Cited by 270
Self-citation
SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
André, T., Lonardi, S., Wong, K. Y. M., Lenz, H., Gelsomino, F., Aglietta, M., Morse, M. A., Cutsem, E. V., McDermott, R., Hill, A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.05.051 · Cited by 9
Self-citation
Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Self-citation
Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update.
Lenz, H., Lonardi, S., Zagonel, V., Cutsem, E. V., Limón, M. L., Wong, M. K., Hendlisz, A., Aglietta, M., Alfonso, P. G., Neyns, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4040 · Cited by 43
Self-citation

See all

Authors: Lenz, H.-J., Van Cutsem, E., Luisa Limon, M., Wong, K. Y. M., Hendlisz, A., Aglietta, M., García-Alfonso, P., Neyns, B., Luppi, G., Cardin, D. B., Dragovich, T., Shah, U., Abdullaev, S., Gricar, J., Ledeine, J.-M., Overman, M. J., & Lonardi, S.
Affiliations: USC Norris Comprehensive Cancer Center (US)
University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium
Hospital Universitario Virgen del Rocio, Sevilla, Spain
Westmead Hospital (AU)
Institut Jules Bordet (BE)
Candiolo Cancer Institute (IT)
Hospital General Universitario Gregorio Marañón (ES)
Universitair Ziekenhuis Brussel (BE)
University of Modena and Reggio Emilia (IT)
Vanderbilt University (US)
Banner MD Anderson Cancer Center (US)
Lehigh Valley Cancer Institute, Allentown, PA
Bristol-Myers Squibb (United States) (US)
The University of Texas MD Anderson Cancer Center (US)
Istituto Oncologico Veneto (IT)
ORCID: Lenz, Heinz-Josef
Van Cutsem, Eric
Luisa Limon, Maria
Hendlisz, Alain
Aglietta, Massimo
Neyns, Bart
Cardin, Dana B.
Overman, Michael James
Lonardi, Sara
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2022-01-10
Volume: 40
Issue: 2
Pages: 161-170
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.21.01015
OpenAlex: W3206775306
Semantic Scholar: 2e81a9ea94ac646baf31c284ca8497f8b3df6f0e
Cited by: 728
References: 30
Citations by year: 2026: 125 · 2025: 148 · 2024: 182 · 2023: 173 · 2022: 93
FWCI: 41.26
Type: journal article
Language: en
Open access: green
biblio.vub.ac.be
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Lirias (submittedVersion)
Funders: Bristol-Myers Squibb
Agilent Technologies (PD-L1 IHC 28-8)
Ono Pharmaceutical
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: nivolumab, ipilimumab, metastatic colorectal cancer, microsatellite instability-high, mismatch repair deficiency, first-line therapy, immune checkpoint inhibitors, combination immunotherapy, objective response rate, progression-free survival, treatment-related adverse events
MeSH terms: Ipilimumab, Nivolumab, Progression-Free Survival, Immune Checkpoint Inhibitors, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Time Factors, Colorectal Neoplasms, Disease Progression, Microsatellite Instability, DNA Mismatch Repair, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks